Profile data is unavailable for this security.
About the company
IXICO plc is engaged in neuroscience imaging and biomarker analytics, using its artificial intelligence (AI)-driven platform to help advance drug development in neurological disorders. The Company is engaged in delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Alzheimer's disease, Parkinson's disease and Huntington's disease. It advances medicine and human health by turning data into clinically meaningful information, providing new insights in neuroscience by supporting pharmaceutical companies across all phases of central nervous system (CNS) clinical research. Its services include imaging biomarkers, trial management, data analytics, consultancy and post-marketing surveillance. Its TrialTracker platform provides a standardized, compliant and efficient workflow for capturing visual read results of MRI, SPECT, PET and CT scans, supporting single, over-read and double adjudicated read paradigms.
- Revenue in GBP (TTM)6.53m
- Net income in GBP-1.65m
- Incorporated1995
- Employees79.00
- LocationIXICO PLC4th Fl, Griffin Court, 15 Long LaneLONDON EC1A 9PNUnited KingdomGBR
- Phone+44 203 763 7499
- Fax+44 207 209 2473
- Websitehttps://ixico.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Roquefort Therapeutics PLC | 0.00 | -882.45k | 1.96m | 1.00 | -- | 0.3975 | -- | -- | -0.0063 | -0.0063 | 0.00 | 0.0302 | 0.00 | -- | -- | 0.00 | -15.04 | -- | -17.23 | -- | -- | -- | -- | -- | -- | -17.40 | 0.0747 | -- | -100.00 | -- | 44.29 | -- | -- | -- |
| ValiRx Plc | 49.78k | -1.78m | 2.56m | 14.00 | -- | 0.3742 | -- | 51.48 | -0.0094 | -0.0094 | 0.0002 | 0.0092 | 0.0147 | 0.00 | 0.6068 | 3,555.71 | -55.35 | -48.98 | -51.45 | -49.62 | 100.00 | -- | -3,775.95 | -16,086.59 | 8.87 | -- | 0.0022 | -- | 418.54 | -- | 5.99 | -- | -37.39 | -- |
| N4 Pharma PLC | 7.07k | -1.07m | 3.95m | 4.00 | -- | 2.24 | -- | 559.17 | -0.0025 | -0.0025 | 0.00002 | 0.0021 | 0.0045 | -- | 0.0756 | 1,767.50 | -71.04 | -59.59 | -74.91 | -63.90 | -- | -- | -15,981.33 | -67,987.22 | -- | -- | 0.00 | -- | 273.33 | -- | 16.60 | -- | -- | -- |
| TheraCryf PLC | 0.00 | -2.01m | 4.51m | 9.00 | -- | 0.9398 | -- | -- | -0.0017 | -0.0017 | 0.00 | 0.0022 | 0.00 | -- | -- | 0.00 | -41.20 | -38.70 | -53.79 | -42.97 | -- | -- | -- | -1,407.46 | -- | -- | 0.00 | -- | -100.00 | -- | 38.13 | -- | -- | -- |
| Ovoca Bio PLC | 0.00 | 65.12k | 5.28m | 1.00 | -- | 2.21 | 81.08 | -- | -0.0064 | -0.0159 | 0.00 | 0.0373 | 0.00 | -- | -- | 0.00 | 3.15 | -30.40 | 3.64 | -33.15 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 99.94 | -- | -- | -- |
| Cizzle Biotechnology Holdings PLC | 0.00 | -1.12m | 6.14m | 67.00 | -- | -- | -- | -- | -0.0028 | -0.0028 | 0.00 | -0.0007 | 0.00 | -- | -- | -- | -190.34 | -146.14 | -433.59 | -169.40 | -- | -- | -- | -- | 0.4766 | -2.42 | -- | -- | -- | -- | -26.15 | -- | -- | -- |
| Futura Medical PLC | 7.93m | -6.29m | 7.41m | 12.00 | -- | 1.27 | -- | 0.9351 | -0.0207 | -0.0207 | 0.0261 | 0.01 | 1.06 | 137.36 | 8.58 | -- | -84.19 | -45.00 | -112.42 | -71.79 | 70.67 | -- | -79.41 | -108.25 | 2.21 | -- | 0.00 | -- | 349.09 | 237.55 | 119.85 | -- | 121.02 | -- |
| OptiBiotix Health PLC | 1.15m | -191.00k | 7.90m | 5.00 | -- | 0.9385 | 564.46 | 6.87 | -0.0018 | -0.0018 | 0.0113 | 0.0815 | 0.134 | 1.93 | 2.88 | 230,200.00 | -2.22 | 17.23 | -2.33 | 17.84 | 45.44 | 50.78 | -16.59 | 189.34 | 3.75 | -- | 0.00 | 94.93 | 35.09 | 3.15 | 11.48 | -- | -- | -- |
| IXICO PLC | 6.53m | -1.65m | 9.50m | 79.00 | -- | 0.8093 | -- | 1.45 | -0.0186 | -0.0186 | 0.073 | 0.1267 | 0.5222 | -- | 3.18 | 82,708.86 | -13.19 | -3.47 | -15.43 | -4.03 | 48.71 | 55.52 | -25.27 | -6.21 | -- | -- | 0.015 | -- | 13.32 | -7.27 | 17.49 | -- | -5.30 | -- |
| Genflow Biosciences PLC | 0.00 | -1.80m | 10.36m | 5.00 | -- | -- | -- | -- | -0.005 | -0.005 | 0.00 | -0.0007 | 0.00 | -- | -- | 0.00 | -197.92 | -- | -648.46 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 14.68 | -- | -- | -- |
| Solvonis Therapeutics PLC | 0.00 | -2.60m | 17.02m | -- | -- | 2.13 | -- | -- | -0.001 | -0.001 | 0.00 | 0.0012 | 0.00 | -- | -- | -- | -44.49 | -- | -54.32 | -- | -- | -- | -- | -- | -- | -645.25 | 0.011 | -- | -100.00 | -- | 53.62 | -- | -- | -- |
| Fusion Antibodies PLC | 1.60m | -1.47m | 20.00m | 24.00 | -- | 25.05 | -- | 12.53 | -0.0144 | -0.0144 | 0.0152 | 0.0064 | 0.9557 | 4.96 | 1.96 | 66,500.00 | -87.84 | -56.24 | -137.88 | -73.67 | 22.06 | 36.41 | -91.92 | -71.05 | 1.45 | -190.63 | 0.3483 | -- | 72.98 | -12.79 | 23.05 | -- | -37.98 | -- |
| Sareum Holdings Plc | 0.00 | -4.44m | 23.47m | 5.00 | -- | 10.04 | -- | -- | -0.0365 | -0.0365 | 0.00 | 0.0169 | 0.00 | -- | -- | 0.00 | -126.85 | -93.37 | -202.14 | -118.41 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -29.77 | -- | -- | -- |
Data as of Feb 09 2026. Currency figures normalised to IXICO PLC's reporting currency: UK Pound GBX
48.77%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Octopus Investments Ltd.as of 08 Dec 2025 | 16.85m | 18.18% |
| BGF Investment Management Ltd.as of 08 Dec 2025 | 12.89m | 13.91% |
| Canaccord Genuity Asset Management Ltd.as of 08 Dec 2025 | 7.47m | 8.06% |
| Unicorn Asset Management Ltd.as of 08 Dec 2025 | 3.86m | 4.16% |
| Hargreaves Lansdown Asset Management Ltd.as of 01 Nov 2025 | 2.54m | 2.74% |
| ICBC Standard Bank Plcas of 01 Nov 2025 | 910.00k | 0.98% |
| HSBC Global Asset Management (UK) Ltd.as of 01 Nov 2025 | 247.00k | 0.27% |
| IG Markets Ltd.as of 01 Nov 2025 | 160.00k | 0.17% |
| Acadian Asset Management LLCas of 01 Nov 2025 | 151.00k | 0.16% |
| Rathbones Investment Management Ltd.as of 01 Nov 2025 | 115.00k | 0.12% |
More ▼
Data from 30 Sep 2025 - 05 Feb 2026Source: FactSet Research Systems Inc.
